MiMedx Group, Inc. announced net sales of $93 million for the fourth quarter of 2024, marking a 7% increase year-over-year. For the full year 2024, net sales reached $349 million, up 9% compared to $321 million in the prior year.
The company reported GAAP net income of $7 million for Q4 2024 and $42 million for the full year. Adjusted EBITDA for the fourth quarter was $20 million, representing 21% of net sales, reflecting continued operational efficiency.
MiMedx ended 2024 with a strong cash position of $104 million, an increase from $82 million at the end of 2023. The company provided a positive outlook for 2025, expecting net sales growth of at least high single-digits and an Adjusted EBITDA margin above 20%, contingent on the planned implementation of future effective LCDs. Additionally, the last material matter associated with historical Audit Committee investigation concluded during 2024, with no material activity expected in future periods.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.